Investor Relations

Corporate Overview

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and neuropsychiatric disorders for both hospital and home settings.

Read more

Why Invest

300+

Years of combined industry experience

2nd

SE is the second most common CNS emergency in the US

1,600

Patients safely treated using therapeutically relevant doses of ganaxolone

1st

Potential treatment for status epilepticus and rare genetic epilepsies that have few or no treatment options

Latest News

View all news

Latest Presentation

Latest Events

View All Events

Latest Quarterly Reports

View All Financial Reports